Your browser doesn't support javascript.
loading
Cholesterol crystals use complement to increase NLRP3 signaling pathways in coronary and carotid atherosclerosis.
Niyonzima, Nathalie; Bakke, Siril S; Gregersen, Ida; Holm, Sverre; Sandanger, Øystein; Orrem, Hilde L; Sporsheim, Bjørnar; Ryan, Liv; Kong, Xiang Yi; Dahl, Tuva Børresdatter; Skjelland, Mona; Sørensen, Kirsten Krohg; Rokstad, Anne Mari; Yndestad, Arne; Latz, Eicke; Gullestad, Lars; Andersen, Geir Ø; Damås, Jan Kristian; Aukrust, Pål; Mollnes, Tom E; Halvorsen, Bente; Espevik, Terje.
Afiliação
  • Niyonzima N; Centre of Molecular Inflammation Research, and Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Olav Kyrres gate 17, Trondheim 7030, Norway.
  • Bakke SS; Centre of Molecular Inflammation Research, and Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Olav Kyrres gate 17, Trondheim 7030, Norway.
  • Gregersen I; Research Institute of Internal Medicine, Oslo University Hospital, Norway; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Norway.
  • Holm S; Research Institute of Internal Medicine, Oslo University Hospital, Norway.
  • Sandanger Ø; Research Institute of Internal Medicine, Oslo University Hospital, Norway; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Norway.
  • Orrem HL; Division of Emergencies and Critical Care, Oslo University Hospital, Oslo, Norway.
  • Sporsheim B; Centre of Molecular Inflammation Research, and Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Olav Kyrres gate 17, Trondheim 7030, Norway.
  • Ryan L; Centre of Molecular Inflammation Research, and Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Olav Kyrres gate 17, Trondheim 7030, Norway.
  • Kong XY; Research Institute of Internal Medicine, Oslo University Hospital, Norway.
  • Dahl TB; Research Institute of Internal Medicine, Oslo University Hospital, Norway.
  • Skjelland M; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Norway; Department of Neurology, Oslo University Hospital, Norway.
  • Sørensen KK; Research Institute of Internal Medicine, Oslo University Hospital, Norway; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Norway.
  • Rokstad AM; Centre of Molecular Inflammation Research, and Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Olav Kyrres gate 17, Trondheim 7030, Norway.
  • Yndestad A; Research Institute of Internal Medicine, Oslo University Hospital, Norway; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Norway.
  • Latz E; Centre of Molecular Inflammation Research, and Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Olav Kyrres gate 17, Trondheim 7030, Norway; Institute of Innate Immunity, Biomedical Center, University of Bonn, Germany.
  • Gullestad L; Department of Cardiology, Oslo University Hospital, Norway; KG Jebsen Center for Cardiac Research, and Center for Heart Failure Research, Oslo University Hospital, Norway.
  • Andersen GØ; Department of Cardiology, Oslo University Hospital, Norway.
  • Damås JK; Centre of Molecular Inflammation Research, and Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Olav Kyrres gate 17, Trondheim 7030, Norway.
  • Aukrust P; Research Institute of Internal Medicine, Oslo University Hospital, Norway; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Norway; Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital, Norway.
  • Mollnes TE; Centre of Molecular Inflammation Research, and Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Olav Kyrres gate 17, Trondheim 7030, Norway; Department of Immunology, Oslo University Hospital, Norway; KG Jebsen TREC, Department of Clinical Medicine, Univ
  • Halvorsen B; Research Institute of Internal Medicine, Oslo University Hospital, Norway; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Norway.
  • Espevik T; Centre of Molecular Inflammation Research, and Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Olav Kyrres gate 17, Trondheim 7030, Norway; The Central Norway Regional Health Authority, St. Olavs Hospital HF, Norway. Electronic address: terje.espevik@nt
EBioMedicine ; 60: 102985, 2020 Oct.
Article em En | MEDLINE | ID: mdl-32927275
ABSTRACT

BACKGROUND:

During atherogenesis, cholesterol precipitates into cholesterol crystals (CC) in the vessel wall, which trigger plaque inflammation by activating the NACHT, LRR and PYD domains-containing protein 3 (NLRP3) inflammasome. We investigated the relationship between CC, complement and NLRP3 in patients with cardiovascular disease.

METHODS:

We analysed plasma, peripheral blood mononuclear cells (PBMC) and carotid plaques from patients with advanced atherosclerosis applying ELISAs, multiplex cytokine assay, qPCR, immunohistochemistry, and gene profiling.

FINDINGS:

Transcripts of interleukin (IL)-1beta(ß) and NLRP3 were increased and correlated in PBMC from patients with acute coronary syndrome (ACS). Priming of these cells with complement factor 5a (C5a) and tumour necrosis factor (TNF) before incubation with CC resulted in increased IL-1ß protein when compared to healthy controls. As opposed to healthy controls, systemic complement was significantly increased in patients with stable angina pectoris or ACS. In carotid plaques, complement C1q and C5b-9 complex accumulated around CC-clefts, and complement receptors C5aR1, C5aR2 and C3aR1 were higher in carotid plaques compared to control arteries. Priming human carotid plaques with C5a followed by CC incubation resulted in pronounced release of IL-1ß, IL-18 and IL-1α. Additionally, mRNA profiling demonstrated that C5a and TNF priming followed by CC incubation upregulated plaque expression of NLRP3 inflammasome components.

INTERPRETATION:

We demonstrate that CC are important local- and systemic complement activators, and we reveal that the interaction between CC and complement could exert its effect by activating the NLRP3 inflammasome, thus promoting the progression of atherosclerosis.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença da Artéria Coronariana / Proteínas do Sistema Complemento / Doenças das Artérias Carótidas / Transdução de Sinais / Colesterol / Proteína 3 que Contém Domínio de Pirina da Família NLR Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença da Artéria Coronariana / Proteínas do Sistema Complemento / Doenças das Artérias Carótidas / Transdução de Sinais / Colesterol / Proteína 3 que Contém Domínio de Pirina da Família NLR Idioma: En Ano de publicação: 2020 Tipo de documento: Article